US Patent 7892546 Anti-CXCR4 antibodies
Patent 7892546 was granted and assigned to Eli Lilly and Company on February, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+301 characters)
Article
Patent abstract
The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07892546 Anti-CXCR4 antibodies US Patent 7892546 Anti-CXCR4 antibodies
Infobox
Patent Number
0789254600
Patent Number
789254600
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078925460
Date of Patent
February 22, 2011
0Patent Application Number
124369250
Date Filed
May 7, 2009
0Official Website
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078925460
Date of Patent
February 22, 2011
0Patent Application Number
124369250
Date Filed
May 7, 2009
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07892546 Anti-CXCR4 antibodies
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07892546
Date of patent
February 22, 2011
Patent application number
12436925
Date Filed
May 7, 2009
Patent primary examiner
Find more entities like US Patent 7892546 Anti-CXCR4 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
